Neuphoria Therapeutics Inc.
NEUP
$4.40
$0.184.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 211,558.11% | 4,347.65% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 35,535.97% | 847.13% | -- | -- |
| Cost of Revenue | 0.00% | -138.96% | 28.08% | -111.32% | -100.34% |
| Gross Profit | 15,649,400.00% | 700.74% | 8.67% | 129.76% | 100.35% |
| SG&A Expenses | -8.27% | -11.68% | -28.48% | -21.35% | -5.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.41% | -10.98% | -27.90% | -27.59% | -17.61% |
| Operating Income | 95.34% | 97.41% | 31.27% | 27.74% | 17.61% |
| Income Before Tax | 94.62% | 130.74% | 59.69% | 48.78% | 27.76% |
| Income Tax Expenses | -436.54% | -167.46% | 0.72% | -33.17% | 37.37% |
| Earnings from Continuing Operations | 97.61% | 132.19% | 60.09% | 49.32% | 27.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.61% | 132.19% | 60.09% | 49.32% | 27.69% |
| EBIT | 95.34% | 97.41% | 31.27% | 27.74% | 17.61% |
| EBITDA | 99.03% | 101.10% | 32.29% | 28.68% | 18.29% |
| EPS Basic | 105.61% | 124.07% | -39.42% | -80,888.03% | -78,692.47% |
| Normalized Basic EPS | 102.37% | 89.27% | -90.11% | -101,629.55% | -98,298.90% |
| EPS Diluted | 105.60% | 124.05% | -39.43% | -80,890.14% | -78,694.52% |
| Normalized Diluted EPS | 102.37% | 89.27% | -90.11% | -101,629.55% | -98,298.90% |
| Average Basic Shares Outstanding | 87.73% | -8.83% | -39.80% | -53.31% | -74.49% |
| Average Diluted Shares Outstanding | 87.73% | -8.83% | -39.80% | -53.31% | -74.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |